Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessing The Risk Of Febrile Neutropenia For Myelosuppressive Chemotherapy In Patients Who Are Receiving Pegfilgrastim On Body Injector As A Prophylaxis Treatment In Real World Setting

Next Previous
Trial Profile

Assessing The Risk Of Febrile Neutropenia For Myelosuppressive Chemotherapy In Patients Who Are Receiving Pegfilgrastim On Body Injector As A Prophylaxis Treatment In Real World Setting

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Chemotherapy induced febrile neutropenia
  • Focus Therapeutic Use

Most Recent Events

  • 11 Dec 2020 Interim results (n=1930) presented at the 43rd Annual San Antonio Breast Cancer Symposium
  • 17 Jan 2020 New trial record
  • 14 Dec 2019 As of 25 June 2019, N=1,048 patients have been enrolled and Two interim analyses will be conducted after 1,000 and 2,000 patients have been enrolled and received study treatment as per at the 42nd Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top